NewAmsterdam Pharma (NAMS) Change in Account Payables (2023 - 2026)

NewAmsterdam Pharma has reported Change in Account Payables for 4 years, with the latest figure at -$793000.0 in Q1 2026.

• Quarterly Change in Account Payables fell 135.23% year-over-year to -$793000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.9 million (up 178.16% YoY) and the FY2025 annual result came in at $4.9 million, up 137.91% from the prior year.
• Change in Account Payables slipped to -$793000.0 in Q1 2026 per NAMS's latest filing, from $5.3 million in the prior quarter.
• Over five years, Change in Account Payables peaked at $12.9 million in Q4 2023 and troughed at -$9.2 million in Q3 2023.
• A 4-year average of -$289384.6 and a median of -$793000.0 in 2026 frame the typical range for Change in Account Payables.
• The widest YoY moves for Change in Account Payables: up 266.34% in 2025, down 219.11% in 2025.
• Over 4 years, Change in Account Payables stood at $12.9 million in 2023, then tumbled by 124.79% to -$3.2 million in 2024, then jumped by 266.34% to $5.3 million in 2025, then plunged by 114.91% to -$793000.0 in 2026.
• According to Business Quant data, Change in Account Payables over the past three periods registered -$793000.0, $5.3 million, and -$2.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.